Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.61
BCR's Cash to Debt is ranked lower than
63% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. BCR: 0.61 )
Ranked among companies with meaningful Cash to Debt only.
BCR' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.81 Max: 4.9
Current: 0.61
0.06
4.9
Equity to Asset 0.32
BCR's Equity to Asset is ranked lower than
82% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. BCR: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
BCR' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.56 Max: 0.77
Current: 0.32
0.28
0.77
Interest Coverage 7.79
BCR's Interest Coverage is ranked lower than
75% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 35.09 vs. BCR: 7.79 )
Ranked among companies with meaningful Interest Coverage only.
BCR' s Interest Coverage Range Over the Past 10 Years
Min: 7.78  Med: 26.85 Max: 60.49
Current: 7.79
7.78
60.49
F-Score: 6
Z-Score: 3.93
M-Score: -2.67
WACC vs ROIC
5.46%
14.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.94
BCR's Operating margin (%) is ranked higher than
66% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. BCR: 10.94 )
Ranked among companies with meaningful Operating margin (%) only.
BCR' s Operating margin (%) Range Over the Past 10 Years
Min: 10.23  Med: 24.06 Max: 39.79
Current: 10.94
10.23
39.79
Net-margin (%) 14.04
BCR's Net-margin (%) is ranked higher than
83% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. BCR: 14.04 )
Ranked among companies with meaningful Net-margin (%) only.
BCR' s Net-margin (%) Range Over the Past 10 Years
Min: 3.96  Med: 17.46 Max: 22.62
Current: 14.04
3.96
22.62
ROE (%) 32.57
BCR's ROE (%) is ranked higher than
95% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. BCR: 32.57 )
Ranked among companies with meaningful ROE (%) only.
BCR' s ROE (%) Range Over the Past 10 Years
Min: 8.19  Med: 21.92 Max: 33.75
Current: 32.57
8.19
33.75
ROA (%) 9.90
BCR's ROA (%) is ranked higher than
81% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. BCR: 9.90 )
Ranked among companies with meaningful ROA (%) only.
BCR' s ROA (%) Range Over the Past 10 Years
Min: 2.7  Med: 14.07 Max: 17.1
Current: 9.9
2.7
17.1
ROC (Joel Greenblatt) (%) 86.48
BCR's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.00 vs. BCR: 86.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BCR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 49.28  Med: 76.67 Max: 148.85
Current: 86.48
49.28
148.85
Revenue Growth (3Y)(%) 8.90
BCR's Revenue Growth (3Y)(%) is ranked higher than
68% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. BCR: 8.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BCR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.7  Med: 10.2 Max: 13.9
Current: 8.9
-0.7
13.9
EBITDA Growth (3Y)(%) -10.20
BCR's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. BCR: -10.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BCR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.5  Med: 11.1 Max: 25.4
Current: -10.2
-18.5
25.4
EPS Growth (3Y)(%) -34.00
BCR's EPS Growth (3Y)(%) is ranked lower than
88% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. BCR: -34.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BCR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34  Med: 11.5 Max: 28.9
Current: -34
-34
28.9
» BCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

BCR Guru Trades in Q4 2015

Tom Gayner 9,000 sh (+125.00%)
Joel Greenblatt 7,682 sh (+94.19%)
Paul Tudor Jones 154,977 sh (+86.97%)
Jim Simons 1,098,500 sh (+23.30%)
John Hussman 10,000 sh (unchged)
Yacktman Fund 900,000 sh (-5.26%)
Donald Yacktman 1,283,759 sh (-12.33%)
Jeremy Grantham 104,075 sh (-17.71%)
Yacktman Focused Fund 140,000 sh (-30.00%)
Ray Dalio 10,786 sh (-50.38%)
Pioneer Investments 446,068 sh (-54.19%)
Vanguard Health Care Fund 226,841 sh (-71.10%)
» More
Q1 2016

BCR Guru Trades in Q1 2016

Joel Greenblatt 150,877 sh (+1864.03%)
Ray Dalio 23,315 sh (+116.16%)
Paul Tudor Jones 225,900 sh (+45.76%)
Jim Simons 1,355,300 sh (+23.38%)
Yacktman Fund 900,000 sh (unchged)
Yacktman Focused Fund 140,000 sh (unchged)
Tom Gayner 9,000 sh (unchged)
Vanguard Health Care Fund Sold Out
John Hussman Sold Out
Donald Yacktman 1,276,894 sh (-0.53%)
Jeremy Grantham 69,375 sh (-33.34%)
Pioneer Investments 289,215 sh (-35.16%)
» More
Q2 2016

BCR Guru Trades in Q2 2016

Louis Moore Bacon 904 sh (New)
Tom Gayner 9,000 sh (unchged)
Jeremy Grantham Sold Out
Yacktman Focused Fund Sold Out
Pioneer Investments 289,061 sh (-0.05%)
Ray Dalio 20,815 sh (-10.72%)
Jim Simons 1,063,200 sh (-21.55%)
Yacktman Fund 650,000 sh (-27.78%)
Donald Yacktman 806,300 sh (-36.85%)
Joel Greenblatt 5,582 sh (-96.30%)
Paul Tudor Jones 1,100 sh (-99.51%)
» More
Q3 2016

BCR Guru Trades in Q3 2016

Steven Cohen 229,200 sh (New)
Jeremy Grantham 98,050 sh (New)
Paul Tudor Jones 126,800 sh (+11427.27%)
Louis Moore Bacon 2,426 sh (+168.36%)
Tom Gayner Sold Out
Pioneer Investments 271,837 sh (-5.96%)
Donald Yacktman 738,964 sh (-8.35%)
Yacktman Fund 550,000 sh (-15.38%)
Jim Simons 797,200 sh (-25.02%)
Joel Greenblatt 3,760 sh (-32.64%)
Ray Dalio 6,915 sh (-66.78%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:XRAY, OTCPK:TRUMF, OTCPK:OCPNY, NAS:ILMN, NYSE:WAT, NYSE:MTD, NAS:HOLX, OTCPK:RSMDF, OTCPK:ESLOY, NYSE:COO, NYSE:WST, NYSE:BAX, OTCPK:SAUHY, NYSE:STE, OTCPK:GNGBY, NYSE:HRC, NYSE:CMN, OTCPK:ANSLY, NAS:ICUI, NAS:PODD » details
Traded in other countries:BR6.Germany,
CR Bard Inc manufactures, distributes and sells medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, and extended care facilities.

C.R. Bard Inc was incorporated in New Jersey in 1923. The Company is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities The Company participates in the markets for vascular, urology, oncology and surgical specialty products. It reports its sales in four product group categories: vascular, urology, oncology and surgical specialties. The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty, (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; peripheral vascular stents, covered stents and vascular grafts; vena cava filters; biopsy devices; and electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters. The Company's urology products include basic drainage products, continence products and urological specialty products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs. The Company's soft tissue repair products consist of hernia repair grafts, including both synthetic and natural-tissue configurations, and hernia fixation devices. The Company competes in the therapeutic and diagnostic medical device markets around the world. Its products are distributed domestically directly to hospitals and other healthcare institutions as well as through numerous hospitals/surgical supply and other medical specialty distributors with whom the Company has distribution agreements. The Company is subject to governmental laws and regulations.

Guru Investment Theses on C.R. Bard Inc

Donald Yacktman Comments on C.R. Bard - Nov 05, 2015

C.R. Bard (NYSE:BCR) was a solid performer in the third quarter. As a result, we reduced the Fund’s position size in Bard.

From Donald Yacktman (Trades, Portfolio)'s third quarter 2015 commentary.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about C.R. Bard Inc

Timothy Ring, CEO and Chairman of C.R. Bard Inc., Sold 92,293 Shares of the Company on Sept. 28 Insider buy
Timothy Ring (Insider Trades), CEO and Chairman of C.R. Bard Inc. (BCR), sold 92,293 shares of the company on Sept. 28, 2016. The average price per share was $227.81, for a total transaction of $21,025,268. C.R. Bard, a multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in vascular, urology, oncology and surgical specialty products, has a market cap of $16.47 billion. Read more...
Insider Trades: C.R. Bard, NVIDIA and Alphabet Largest insider trades of the week
The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the "Insiders" tab and changing the settings for All Insider Buys to “200,000sh+” duration to "September 2016” and “September 2016” and All Insider Sales to “$5,000,000+”. Read more...
Yacktman Fund Hopeful After Second Quarter Report Fund comments on PepsiCo, Fox
The AMG Yacktman Fund (Trades, Portfolio) (YACKX) gave their second quarter update on July 27. Joe Maccone from Affiliated Managers Group Fund (AMG) moderated the meeting. Stephen Yacktman and Jason Subotky, the portfolio managers at Yacktman Asset Management, gave their views on the portfolio’s performance as well as discussed their major stock purchases and sales. Read more...
The Yacktman Focused Fund Sells Out of C.R. Bard Inc. C.R. Bard reached its 52-week high during the second quarter
During the second quarter, the Yacktman (Trades, Portfolio) Focused Fund sold out its remaining 140,000 shares of C.R Bard (NYSE:BCR) at at an average price of $216.98. The Yacktman (Trades, Portfolio) Focused Fund saw a 66% increase in its investment in C.R. Bard Inc. since the first quarter of 2011. Read more...
5 Companies Achieve 52-Week Highs C.R. Bard, Tim Hortons, Thermo Fisher, Fiserv, Molson Coors reach landmarks
According to GuruFocus list of 52-week highs, these guru stocks have reached their 52-week highs. Read more...
Dividends’ True Contribution to Total Return May Surprise You Academic research has given mixed conclusions
In recent years, dividends’ contribution to total return has been one of the most heavily-studied topics in the investment world. Several conclusions about the contribution that dividends make to total return have been claimed. However, these conclusions vary greatly. I have seen studies claiming that 90% of returns are attributed to dividends, several claiming 50% or more, and others arguing for a 30% contribution. Ironically, they all seem to be correct depending on the data-sets and/or timeframes being measured. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.29
BCR's P/E(ttm) is ranked lower than
58% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.70 vs. BCR: 31.29 )
Ranked among companies with meaningful P/E(ttm) only.
BCR' s P/E(ttm) Range Over the Past 10 Years
Min: 14.25  Med: 23.3 Max: 154.75
Current: 31.29
14.25
154.75
Forward P/E 19.65
BCR's Forward P/E is ranked higher than
64% of the 36 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.22 vs. BCR: 19.65 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.29
BCR's PE(NRI) is ranked lower than
60% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.99 vs. BCR: 31.29 )
Ranked among companies with meaningful PE(NRI) only.
BCR' s PE(NRI) Range Over the Past 10 Years
Min: 14.25  Med: 23.23 Max: 154.75
Current: 31.29
14.25
154.75
Price/Owner Earnings (ttm) 396.95
BCR's Price/Owner Earnings (ttm) is ranked lower than
96% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. BCR: 396.95 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BCR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.25  Med: 23.86 Max: 434.61
Current: 396.95
12.25
434.61
P/B 8.97
BCR's P/B is ranked lower than
90% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.12 vs. BCR: 8.97 )
Ranked among companies with meaningful P/B only.
BCR' s P/B Range Over the Past 10 Years
Min: 3.22  Med: 4.64 Max: 11.04
Current: 8.97
3.22
11.04
P/S 4.34
BCR's P/S is ranked lower than
64% of the 222 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.98 vs. BCR: 4.34 )
Ranked among companies with meaningful P/S only.
BCR' s P/S Range Over the Past 10 Years
Min: 2.56  Med: 3.65 Max: 5.06
Current: 4.34
2.56
5.06
PFCF 42.54
BCR's PFCF is ranked lower than
76% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.87 vs. BCR: 42.54 )
Ranked among companies with meaningful PFCF only.
BCR' s PFCF Range Over the Past 10 Years
Min: 10.1  Med: 17.68 Max: 49.36
Current: 42.54
10.1
49.36
POCF 34.28
BCR's POCF is ranked lower than
83% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.05 vs. BCR: 34.28 )
Ranked among companies with meaningful POCF only.
BCR' s POCF Range Over the Past 10 Years
Min: 9.09  Med: 15.02 Max: 40.02
Current: 34.28
9.09
40.02
EV-to-EBIT 23.90
BCR's EV-to-EBIT is ranked lower than
57% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.14 vs. BCR: 23.90 )
Ranked among companies with meaningful EV-to-EBIT only.
BCR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 15.1 Max: 49.4
Current: 23.9
8
49.4
EV-to-EBITDA 18.20
BCR's EV-to-EBITDA is ranked lower than
58% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.65 vs. BCR: 18.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
BCR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 13 Max: 31.5
Current: 18.2
7.2
31.5
PEG 45.29
BCR's PEG is ranked lower than
98% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. BCR: 45.29 )
Ranked among companies with meaningful PEG only.
BCR' s PEG Range Over the Past 10 Years
Min: 0.94  Med: 1.55 Max: 45.29
Current: 45.29
0.94
45.29
Shiller P/E 42.09
BCR's Shiller P/E is ranked lower than
53% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.92 vs. BCR: 42.09 )
Ranked among companies with meaningful Shiller P/E only.
BCR' s Shiller P/E Range Over the Past 10 Years
Min: 23.36  Med: 30.42 Max: 48.19
Current: 42.09
23.36
48.19
Current Ratio 2.63
BCR's Current Ratio is ranked higher than
55% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. BCR: 2.63 )
Ranked among companies with meaningful Current Ratio only.
BCR' s Current Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.52 Max: 5.88
Current: 2.63
1.16
5.88
Quick Ratio 2.07
BCR's Quick Ratio is ranked higher than
64% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. BCR: 2.07 )
Ranked among companies with meaningful Quick Ratio only.
BCR' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.98 Max: 4.72
Current: 2.07
0.62
4.72
Days Inventory 119.13
BCR's Days Inventory is ranked higher than
54% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.20 vs. BCR: 119.13 )
Ranked among companies with meaningful Days Inventory only.
BCR' s Days Inventory Range Over the Past 10 Years
Min: 93.65  Med: 104.83 Max: 119.13
Current: 119.13
93.65
119.13
Days Sales Outstanding 45.99
BCR's Days Sales Outstanding is ranked higher than
79% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.14 vs. BCR: 45.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.99  Med: 59.67 Max: 63.66
Current: 45.99
45.99
63.66
Days Payable 26.00
BCR's Days Payable is ranked lower than
85% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.76 vs. BCR: 26.00 )
Ranked among companies with meaningful Days Payable only.
BCR' s Days Payable Range Over the Past 10 Years
Min: 18.23  Med: 20.88 Max: 28.74
Current: 26
18.23
28.74

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.47
BCR's Dividend Yield is ranked lower than
84% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. BCR: 0.47 )
Ranked among companies with meaningful Dividend Yield only.
BCR' s Dividend Yield Range Over the Past 10 Years
Min: 0.4  Med: 0.7 Max: 0.9
Current: 0.47
0.4
0.9
Dividend Payout 0.15
BCR's Dividend Payout is ranked higher than
82% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. BCR: 0.15 )
Ranked among companies with meaningful Dividend Payout only.
BCR' s Dividend Payout Range Over the Past 10 Years
Min: 0.03  Med: 0.17 Max: 1.31
Current: 0.15
0.03
1.31
Dividend Growth (3y) 5.70
BCR's Dividend Growth (3y) is ranked lower than
68% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. BCR: 5.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BCR' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 3.2  Med: 5.7 Max: 7.4
Current: 5.7
3.2
7.4
Forward Dividend Yield 0.50
BCR's Forward Dividend Yield is ranked lower than
84% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.52 vs. BCR: 0.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.61
BCR's Yield on cost (5-Year) is ranked lower than
82% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.89 vs. BCR: 0.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BCR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.52  Med: 0.91 Max: 1.18
Current: 0.61
0.52
1.18
3-Year Average Share Buyback Ratio 3.40
BCR's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. BCR: 3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.7  Med: 2.4 Max: 5.3
Current: 3.4
-0.7
5.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.89
BCR's Price/Projected FCF is ranked higher than
54% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. BCR: 1.89 )
Ranked among companies with meaningful Price/Projected FCF only.
BCR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.51 Max: 2.26
Current: 1.89
0.91
2.26
Price/DCF (Earnings Based) 2.93
BCR's Price/DCF (Earnings Based) is ranked lower than
71% of the 17 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. BCR: 2.93 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.20
BCR's Price/Median PS Value is ranked lower than
60% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.08 vs. BCR: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
BCR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 0.85 Max: 1.37
Current: 1.2
0.37
1.37
Earnings Yield (Greenblatt) (%) 4.19
BCR's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 228 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. BCR: 4.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BCR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2  Med: 6.6 Max: 12.5
Current: 4.19
2
12.5
Forward Rate of Return (Yacktman) (%) 6.77
BCR's Forward Rate of Return (Yacktman) (%) is ranked lower than
61% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.02 vs. BCR: 6.77 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BCR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.5  Med: 17.7 Max: 22.8
Current: 6.77
6.5
22.8

More Statistics

Revenue (TTM) (Mil) $3,618
EPS (TTM) $ 6.70
Beta0.46
Short Percentage of Float1.72%
52-Week Range $172.21 - 239.43
Shares Outstanding (Mil)73.53

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 3,694 3,907 4,125
EPS ($) 9.98 10.69 6.51
EPS w/o NRI ($) 9.98 10.69 6.51
EPS Growth Rate
(3Y to 5Y Estimate)
65.05%
Dividends Per Share ($) 0.97 1.02 1.22
» More Articles for NYSE:BCR

Headlines

Articles On GuruFocus.com
Dividend Aristocrats in Focus Part 25: CR Bard Nov 01 2016 
Timothy Ring, CEO and Chairman of C.R. Bard Inc., Sold 92,293 Shares of the Company on Sept. 28 Oct 01 2016 
Insider Trades: C.R. Bard, NVIDIA and Alphabet Sep 30 2016 
The Yacktman Focused Fund Sells Out of C.R. Bard Inc. Jul 19 2016 
5 Stocks Hit 52-Week High Prices Jul 11 2016 
5 Companies Have Hit 52-Week Highs Jun 21 2016 
5 Companies Achieve 52-Week Highs Jun 07 2016 
Dividends’ True Contribution to Total Return May Surprise You Mar 24 2016 
Medical Products Company CR Bard Has Stable Business Mar 09 2016 
The Conundrum in Health Care Investing Mar 06 2016 

More From Other Websites
Bard to Present at the Citi Healthcare Conference Nov 30 2016
Bard to Present at the Piper Jaffray Healthcare Conference Nov 23 2016
BARD C R INC /NJ/ Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... Nov 22 2016
CR Bard (BCR) Sees Hammer Chart Pattern: Time to Buy? Nov 17 2016
C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bullish Manner : BCR-US :... Nov 09 2016
Bard to Present at the Stifel Healthcare Conference Nov 08 2016
Dividend Aristocrats in Focus Part 25: CR Bard Nov 01 2016
BARD C R INC /NJ/ Financials Nov 01 2016
ETF’s with exposure to C.R. Bard, Inc. (New Jersey) : October 28, 2016 Oct 28 2016
BARD C R INC /NJ/ Files SEC form 10-Q, Quarterly Report Oct 26 2016
C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : October 24th, 2016 (record date) : By the... Oct 26 2016
C.R. Bard (BCR) Beats Q3 Earnings & Sales, FY16 View Up Oct 26 2016
C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q3, 2016 By the Numbers : October 26, 2016 Oct 26 2016
Edited Transcript of BCR earnings conference call or presentation 25-Oct-16 9:00pm GMT Oct 26 2016
C R Bard Inc Earnings Call scheduled for 5:00 pm ET today Oct 25 2016
BARD C R INC /NJ/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 25 2016
C.R. Bard beats Street 3Q forecasts Oct 25 2016
C.R. Bard beats Street 3Q forecasts Oct 25 2016
Bard Announces Third Quarter Results Oct 25 2016
Q3 2016 C R Bard Inc Earnings Release - After Market Close Oct 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)